Patent ID: 11866503
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A method for treating asthma in a subject in need thereof, the method comprising administering to the subject one or more doses of a therapeutically effective amount of an interleukin-33 (IL-33) antagonist in combination with one or more doses of a therapeutically effective amount of an interleukin-4 receptor (IL-4R) antagonist, wherein the IL-33 antagonist is a monoclonal antibody comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 276, 278, and 280, respectively, and a heavy chain variable region (HCVR) comprising an amino acid sequence with 10 or fewer amino acid substitutions relative to SEQ ID NO: 274, and three light chain complementarity determining regions, LCDR1, LCDR2, and LCDR3, comprising the amino acid sequences of SEQ ID NOs: 284, 286, and 288, respectively, and a light chain variable region (LCVR) comprising an amino acid sequence with 10 or fewer amino acid substitutions relative to SEQ ID NO: 282, and wherein the IL-4R antagonist is a monoclonal antibody comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 339, 340, and 341, respectively, and a HCVR comprising an amino acid sequence with 10 or fewer amino acid substitutions relative to SEQ ID NO: 337, and three light chain complementarity determining regions, LCDR1, LCDR2, and LCDR3, comprising the amino acid sequences of SEQ ID NOs: 342, 343, and 344, respectively, and a LCVR comprising an amino acid sequence with 10 or fewer amino acid substitutions relative to SEQ ID NO: 338.